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Abstract
Antisense therapy has recently been demonstrated with great potential for targeted exon skipping and restoration of
dystrophin production in cultured muscle cells and in muscles of Duchenne Muscular Dystrophy (DMD) patients.
Therapeutic values of exon skipping critically depend on efficacy of the drugs, antisense oligomers (AOs). However, no
animal model has been established to test AO targeting human dystrophin exon in vivo systemically. In this study, we
applied Vivo-Morpholino to the hDMD/mdx mouse, a transgenic model carrying the full-length human dystrophin gene
with mdx background, and achieved for the first time more than 70% efficiency of targeted human dystrophin exon
skipping in vivo systemically. We also established a GFP-reporter myoblast culture to screen AOs targeting human
dystrophin exon 50. Antisense efficiency for most AOs is consistent between the reporter cells, human myoblasts and in the
hDMD/mdx mice in vivo. However, variation in efficiency was also clearly observed. A combination of in vitro cell culture and
a Vivo-Morpholino based evaluation in vivo systemically in the hDMD/mdx mice therefore may represent a prudent
approach for selecting AO drug and to meet the regulatory requirement.
Citation: Wu B, Benrashid E, Lu P, Cloer C, Zillmer A, et al. (2011) Targeted Skipping of Human Dystrophin Exons in Transgenic Mouse Model Systemically for
Antisense Drug Development. PLoS ONE 6(5): e19906. doi:10.1371/journal.pone.0019906
Editor: Gisela Nogales-Gadea, University Hospital Vall d’Hebron, Spain
Received November 19, 2010; Accepted April 20, 2011; Published May 17, 2011
Copyright:  2011 Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Carolinas Muscular Dystrophy Research Endowment at the Carolinas HealthCare Foundation and Carolinas Medical
Center, Charlotte, NC; Charley’s Fund, MA, USA; and by U.S. Army Medical Research, Department of Defense (W81XWH-05-1-0616). The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: qi.lu@carolinashealthcare.org (QLL); bo.wu@carolinashealthcare.org (BW)
. These authors contributed equally to this work.
Introduction
Antisense therapy has been shown promising for the treatment
of Duchenne muscular dystrophy (DMD) [1–16]. DMD, affecting
approximately 1 of 3500 new-born boys, is a severe x-linked
muscle wasting disease caused by nonsense and out of frame
mutations of the human DMD gene [17]. The dystrophin gene is
one of the largest genes in the human genome containing 79 exons
spanning more than 2.3 million base pairs. The muscle form of
dystrophin consists of four structural domains: amino terminal,
rod, cysteine-rich, and carboxy terminal. The rod domain where
most DMD mutations occur spans more than half of the length of
the protein with limited functions. AO therapy is applicable to
nearly all types of mutations occurring in this rod region and is
predicted to be able to transform more than 60% DMD to near-
normal phenotypes or milder Becker muscular dystrophies [18–
20]. The potential therapeutic effect of AOs was initially
demonstrated in dystrophic mdx muscle cells that harbor a
nonsense point mutation in the exon 23, resulting in the lack of
dystrophin expression [1]. 2’O methyl phosphorothioate
(2OMePS) AOs induced functional amount of dystrophin
expression in tibialis anterior (TA) muscles by local injection and
further showed systemic effect in body-wide muscles [4,5].
Phosphorodiamidate morpholinos (PMO) have been reported
with higher efficiency and functional levels of dystrophin
production in body-wide skeletal muscles in mdx mice and
dystrophic dog [6,10]. More recently, we and others demonstrated
that arginine-rich peptides and dendrimeric octaguanidine
conjugated morpholino (PPMO and Vivo-PMO) are able to
restore the reading frame and produce almost normal levels of
dystrophin protein in body-wide skeletal and cardiac muscles in
the mdx mice [7,8]. Repeated injections of PPMO and Vivo-PMO
can maintain the levels of dystrophin expression for up to 3
months without obvious toxicity. The applicability of AO therapy
has now been indicated in Phase I/II clinical trials with both
2OMePS AOs and PMO targeting human dystrophin exon 51 in
DMD patients [13,16]. More recently, systemic treatment of
DMD patients with PMO was reported to induce detectable
amount of dystrophin protein in sampled skeletal muscles of all
patients, although considerable variation in skipping efficiency was
also clearly observed within the trial population. Patients after
systemic administration of 2OMePS AO (PRO051) targeting
human dystrophin exon 51 have been reported with improvement
in muscle function [16].
AO-mediated exon skipping is a RNA-sequence-specific
therapy. Optimal AO sequences require to be identified by
screening. Currently both human myoblasts and fibroblasts from
normal individual and DMD patients have been used for
identifying AOs with efficacy to specifically skip the targeted
exons [2,11,12,21–24]. While the AOs being used in current
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cultures, the degree of relevance for each selected AO targeting
many other dystrophin exons using such cell cultures to exon
skipping in human in vivo remains to be determined. While most
AOs selected in cell culture were reported with expected exon
skipping efficiency in vivo, discrepancy in skipping efficiency
between in cell culture and in vivo has been reported in the
selection of AOs targeting dog dystrophin exon [10]. Thus, selected
AOthroughmyoblastculturesonlymaynotbe sufficientfortheAO
drug development. To overcome the potential difference in exon
skipping efficiency and specificity between myoblasts in vitro and
myofibers invivo,ex-vivomuscle culture has been explored to verify
the efficacy of selected AOs. However, muscle fibers degrade in
culture within 2 days and exon skipping effect occurs most
prominently after 5 days. Thus the exon skipping observed in such
culture is in fact the effect of AOs on fibroblasts and myoblasts grew
out from the muscle tissue plants [9].The lack of reliable systems for
screening AO targeting many human dystrophin exons, especially
the lack of animal models for establishing systemic efficacy poses a
challenge for AO drug development. Efforts have been made to
establish animal models for in vivo testing of AO targeting human
dystrophin exons [25,26]. Most noticeable was the creation of the
humanized (h)DMD mouse containing a complete copy of the
human DMD gene integrated in chromosome 5 [25]. However, the
expression of the normal human dystrophin lends the mouse model
phenotypically normal even having the mdx background. This has
prevented the animal model from being effective for testing AOs
with the most widely used chemistries including 2OMePS AOs and
PMO. This is because effective delivery of these oligos depends on
leaky membrane in dystrophic muscle, thus cannot be achieved in
normal muscles.
In this study, we investigated the value of a GFP reporter based
myoblast culture system for selection of AOs targeting human
dystrophin exon in combination with human myoblast cultures.
Most AO showed similar efficiencies in both the GFP reporter
myoblasts and human myoblasts with the highly effective AO for
skipping human dystrophin exon 50 being identified in both cell
types. The GFP reporter provided most consistent results with
signals readily quantifiable for direct comparison of exon skipping
efficiency. However, variation in relative efficiency between cell
cultures and in vivo was observed with different AOs. Examination
of selected AOs as Vivo-PMO revealed high levels of human
dystrophin exon 50 skipping in body-wide muscles including
cardiac muscle in the hDMD/mdx mice, suggesting that hDMD/
mdx mouse is a highly valuable model for demonstrating systemic
efficacy of selected AO targeting human dystrophin exons. We
conclude that a multi-model screening system combining the use
of cell cultures in vitro and the hDMD/mdx mouse in vivo could
reduce potential risk of variation in efficiency between cell culture
and in vivo and represents a more systematic approach for
identifying AOs of high efficacy, thus better suited to meet the
regulatory requirement for AO drug development.
Materials and Methods
Vector constructions and cell culture
The construction of the human dystrophin exon 50/GFP
reporter vector was based on the procedure reported previously
[27–30]. The human dystrophin exon 50 flanked by 600 bps of its
respective intronic sequences (intron 49 on the 59 side and intron
50 on the 39 side) was amplified from DNA of human myoblasts.
The sequence was inserted into the middle of the b-globin intron
sequence which was placed inside the coding sequence of GFP
gene under the control of actin promotor. C2C12 mouse
myoblasts were transfected with the vector by electroporation
and the transfected cells were selected by geneticin (G418). The
transfected cells (C2C12hE50) were then maintained in high-
glucose Dulbecco’s modified Eagle’s medium (DMEM, Gibco,
Carlsbad, CA) with 10% heat inactivated fetal bovine serum
(Gibco, Carlsbad, CA) and 1% penicillin/streptomycin at 37uC
with 5% CO2. Normal human myoblasts were cultured in skeletal
muscle growth medium (Cell applications Inc, San Diego, CA).
DMD patient-derived skin fibroblasts were maintained in RPMI
(Gibco, Carlsbad, CA), 10% heat inactivated fetal bovine serum,
2% L-glutamine, and 1% penicillin/streptomycin. For PMO
delivery to the cells, Endo porter (Genetools, Philomath, OR) was
used according to the manufacture’s instruction. For 2OMePS AO
delivery, Lipofectamine (invitrogen, Carlsbad, CA) was used
according to the manufacture’s instruction.
Visualization of GFP by fluorescence microscopy and flow
cytometric analysis
Cells, 48 hours after the AO treatment, were visualized using an
Olympus IX71 inverted fluorescent microscope. Digital images of
both Fluorescence and transmit light were taken using the
Olympus DP Controller and DP Manager software. Percentage
of GFP positive cells was obtained by counting the GFP positive
cells under fluorescence light and total number of cells under
transmit light (500 cells in the same fields) before the cells were
subjected to flow cytometry analysis. Then, cells were examined
using flow cytometry to quantitatively gauge the GFP expression
level. Cells were washed with PBS (16) and released from culture
vessel with 0.05% Trypsin-EDTA, neutralized by FBS, pelleted by
centrifugation and then re-suspended in 1 ml PBS. Samples were
run on a Calibur flow cytometer (BD, Franklin Lakes, NJ). 2610
4
cells were counted and analyzed with CellQuest Pro (BD, Franklin
Lakes, NJ) software package.
RT-PCR and Nested-PCR analysis for cell cultures
ForRT-PCRAnalysis, cellswereinitiallywashed twice with PBS,
andRNAwas extractedwith TriZol reagent (Invitrogene,Carlsbad,
CA) according to manufacturer’s instructions. RNA was stored at
280uC for later use. RT-PCR was performed with RT-PCR
Master Mix (USB, Cleveland, Ohio) to amplify the sequence of
interest. 100 ng of template RNA was used for each 25 ml RT-PCR
reaction. The primer sequences for the RT-PCR of C2C12
hDysE50 were eGFPF: 59 – ATGGTGAGCAAGGGCGAGGA-
GCTG – 39; eGFPR: 59 – CTGCACGCCGTAGGTCAGG-
GTGGT – 39. The conditions were 43uC for 15 minutes, 94uC for
2 minutes, then cycled 30 times at 94uC for 30 seconds, 65uC for
30 seconds, and 68uC for 1 minute. The primer sequences for the
RT-PCR of normal human myoblasts and DMD patient-derived
fibroblasts were Ex47/48F3, 59 – GTGGATAAAGGTTTCCA-
GAGC – 39 and Ex53/52R3, 59 – GAATTCTTTCAATTCGA-
TCCGTA – 39. The conditions were 43uC for15 minutes, 94uC for
2 minutes, then cycled 30 times at 94uC for 30 seconds, 55uC for
30 seconds, 68uC for 1 minute, and 68uC for 5 minutes. The
primer sequences for the Nested-PCR of normal human myoblasts
and DMD patient-derived skin fibroblasts were Ex48F2, 59 –T C -
TGCTGCTGTGGTTATCTC – 39 Ex52R2, 59 – TTTTG-
GGCAGCGGTAATGAG – 39. The conditions were 94uC for
2 minutes, then cycled 30 times at 94uC for 30 seconds, 55uC for
30 seconds, 72uC for 1 minute, and 72uC for 5 minutes. The
products were examined by electrophoresis on a 2% agarose gel.
The intensity of 2 bands representing transcripts with and without
targeted exon skipping was measured with the NIH ImageJ 1.42.
The total measurement of the 2 bands was considered as 100%.
50% skipping efficiency is defined as the signal intensity of the band
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the band representing transcripts without targeted exon skipping.
Animals, oligonucleotides and in vivo delivery methods
and Ethical statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of IACUC Carolinas Medical Center (Breeding
protocol: 01-08-06A; Experimental protocol: 01-08-07A). All
injection was performed under isoflurane anesthesia, and all
efforts were made to minimize suffering.
Five C57, mdx, hDMD/mdx mice aged 5–7 weeks were used for
each group unless specified otherwise [25]. The three of PMOs
conjugated with a dendrimeric octaguanidine (Vivo-hE50AO23
PMO, Vivo-hE50AO5PMO, Vivo-hE50AO12PMO) for targeting
exon 50 of the human dystrophin gene, and Vivo-PMOE23 (+7–18)
against the boundary sequences of the exon 23 and intron 23 of
mouse dystrophin gene were used. Vivo-PMOs were prepared in 40
or 100 ml saline and administrated by intramuscular or retraorbital
injections.
Mice were killed at desired time points, and muscles were snap-
frozen in liquid nitrogen-cooled isopentane and stored at 280uC.
Antibodies and Immunohistochemistry
Sections of 6 mm were cut from at least two–thirds of muscle
length of TA, quadriceps, biceps, and gastrocnemius at 100 mm
intervals and at least 10 levels from all other muscles including
heart, diaphragm, intercostals, and abdominal muscles at 100 mm
intervals. The intervening muscle sections were collected either for
RT-PCR analysis. Sections were also stained with hematoxylin
and eosin for histological assessment.
RNA Extraction and RT-PCR for mice muscles
Collected Sections were homogenized in TRIzol (Invitrogene,
Carlsbad, CA) by using an Ultra-Turrax homogenizer (Janke and
Kunkel, Staufen, Germany). RT-PCR for testing mouse exon 23
skipping was done as described previously [7]. Total RNA was
then extracted, and 100 ng of RNA template was used for a 50 ml
RT-PCR with RT-PCR Master Mix (USB, Cleveland, Ohio). The
primer sequences for testing hE50 skipping were Ex47/48F3, and
Ex53/52R3 (for sequences see above) to amplify mRNA from
exons 47 to 53. A total of 30 cycles were carried out for the RT-
PCR. Bands with the expected size for the transcript with hE50
deleted were extracted and sequenced. The intensity of the bands
was measured with the NIH ImageJ 1.42 and percentage of exon
skipping was calculated with the intensity of the 2 bands
representing both unskipped and skipped exons as 100%.
Measurement of serum creatine kinase and other
components
Mouse blood was taken immediately after cervical dislocation
and centrifuged at 1500 rpm for 3 min. Serum was separated and
stored at 280uC. The level of serum components was determined
by Charles Riverside Laboratories.
Results
Targeting human dystrophin exon 50 in C2C12/GFP
reporter myoblasts
To identify potent AOs for targeted skipping of human
dystrophin exon 50 (hE50), we synthesized a total of 25 AOs as
2OMePS (referred as hE50AO#PS) to cover more than two
thirds of the hE50 and the two flanking intron sequences. Two
exonic splicing enhancer (ESE) sequences (gaccacua and uacuuc)
with SC35 score of 5.17 and SRp55 score of 3.22 determined by
the program of ESE Finder (version 2, http://rulai.cshl.edu/
tools/ESE) were also covered by two AOs, hE50AO14PS and
hE50AO16PS (Table 1). The hE50AO12PS AO previously
reported to be effective for hE50 skipping in human myoblasts
was also included [11]. As described previously, a vector
expressing GFP and the hE50 was created [30]. The GFP gene
in the reporter construct is split into 2 fragments (exons) by the
insertion of the human b-globulin intron sequence which is
spliced out during the transcription process. The insertion of
hE50 (including its two flanking intronic sequences) disrupts the
reading frame of the GFP, resulting in no GFP protein
expression. Effective antisense oligonucleotides targeting the
hE50 will be able to remove the dystrophin exon and restore
the GFP reading frame. The selected C2C12 myoblast clone
transfected with the GFP/hE50 vector expressed high levels of
GFP/hE50 chimeric mRNA (termed C2C12hE50), but with no
detectable transcripts with hE50 skipped (Figure 1A, Control
lane). Thus the cell line provides the high potential to distinguish
the efficiency of exon skipping. Consistently, leaky GFP
expression was barely detectable (in less than 0.2% cells with
weak GFP signal detected under fluorescence microscope)
(Figure 1B and C left panels). Thus, the levels of GFP expression
represent the degrees of exon skipping efficiency by individual
AO. All the 2OMePS oligomers were examined with the
C2C12hE50 cells initially at the concentration of 1 mM. Most
of the oligomers did not enhance the GFP expression at this dose
(Table 1). Significant increase in the levels of GFP expression was
observed in the cells treated with hE50AO12PS, hE50AO5PS
and hE50AO23PS, at the rates up to 8%, 21% and 28%
respectively in repeated experiments (Table 1 and Figure 1B).
To examine the potential variation in targeting efficiency with
different chemistries, we synthesized and tested 7 AO sequences
including the 3 most effective ones as PMOs (referred as
hE50AO#PMO) at 1 mM concentration and the GFP expression
was examined 48 hours after treatment (Table 1). The efficiency of
hE50 skipping with the PMO chemistries was consistent to the
2OMePS oligomers of the same sequences and the highest efficiency
was also obtained in the cells treated with hE50AO12PMO,
hE50AO5PMO, hE50AO23PMO, hE50AO13PMO, hE50AO
6PMO and hE50AO24PMO. Cells treated with hE50AO23PMO
produced up to 40% of GFP positive cells in repeated experiments (3
times) (Figure 1C). The signal intensity and percentage of positive
cells were generally higher with PMO than with 2OMePS of same
sequence at the same dose (Figure 1B, C and Table 1). The
inductions of GFP expression by the PMOs were further confirmed
by flow cytometry analysis. As illustrated in the figure 1D, less than
1% GFP positive cells was recorded in the control untreated
C2C12hE50 cells, but up to 29.44% and 33.48% in the cells treated
with 1 mM concentration of hE50AO5PMO and hE50AO23PMO,
respectively. Expected removal of the hE50 was confirmed by RT-
PCR (Figure 1A).
Screening antisense oligonucleotide targeting human
dystrophin exon 50 in normal human myoblasts
All 2OMePS oligomers were also examined at 1 mM concen-
tration in the normal human myoblasts. Two days after
transfection, the cells were harvested and hE50 skipping was
examined by RT-PCR and Nested-PCR. Gel analysis demon-
strated transcripts corresponding to dystrophin mRNA with hE50
skipped in the cells treated with the following 7 AOs, hE50A
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hE50AO22PS and hE50AO23PS (Table 1). Three of them,
hE50AO5PS, hE50AO12PS and hE50AO23PS revealed strongest
bands of RT-PCR and Nested-PCR products representing hE50
skipping with the efficiencies up to 29%, 25% and 65%
respectively (Figure 2A). The overall highest levels of skipping
efficiency were detected with hE50AO23PS and confirmed by
repeated (3 times) experiments.
We also examined 7 PMOs in the human myoblasts (Table 1).
The efficiency of exon skipping was similar to that obtained by the
equivalent 2OMePS AOs at the same 1 mM concentration. The
hE50AO5PMO and hE50AO12PMO were effective for specific
hE50 skipping at approximately 28% and 45% rate respectively,
whereas no hE50 skipping was detected with the hE50AO
14PMO, hE50AO26PMO and hE50AO27PMO (Table 1). The
highest efficiency for hE50 skipping was again detected in the cells
treated with hE50AO23PMO, accounting for approximately 85%
of the total amplified mRNA signal (Figure 2B). The specificity of
the hE50 skipping was confirmed by sequencing of the bands with
the expected size (Figure 2C).
Table 1. List of AO compounds, the sequence and size of AOs and the summary of their exon skipping effect.
AON Target 29OMe PS AON Sequence L GFP hM DMD
hE50 AO1PS 224+85 9–AACUUCCUCUUUAACAGAAAAGCAUACACAUU–39 32 bp - - N/D
hE50 AO2PS 219215 9–CUUUAACAGAAAAGCAUAC–39 19 bp - - N/D
hE50 AO3PS 219+15 9–UCUUUAACAGAAAAGCAUAC–39 20 bp - - N/D
hE50 AO4PS 219+35 9–CCUCUUUAACAGAAAAGCAUAC–39 22 bp 4% 3% N/D
hE50 AO5PS 219+85 9–AACUUCCUCUUUAACAGAAAAGCAUAC–39 27 bp 21% 29% N/D
hE50 AO6PS 219+13 59–CUUCUAACUUCCUCUUUAACAGAAAAGCAUAC–39 32 bp 3% ,1% N/D
hE50 AO7PS 213+35 9–CCUCUUUAACAGAAAA–39 16 bp - - N/D
hE50 AO8PS 214+85 9–AACUUCCUCUUUAACAGAAAAG–39 22 bp - - N/D
hE50 AO9PS 29+85 9–AACUUCCUCUUUAACAG–39 17 bp - - N/D
hE50 AO10PS 29+21 59–GCUCAGAUCUUCUAACUUCCUCUUUAACAG-39 30 bp - - N/D
hE50 AO11PS 28+85 9–AACUUCCUCUUUAACA–39 16 bp - - N/D
hE50 AO12PS +2+30 59–CCACUCAGAGCUCAGAUCUUCUAACUUCC–39 29 bp 8% 25% N/D
hE50 AO13PS +11+27 59–CUCAGAGCUCAGAUCUU–39 17 bp 2% 4% N/D
hE50 AO14PS +42+58 59–GCUCUUGAAGUAAACGG–39 17 bp - - N/D
hE50 AO15PS +85+102 59–AAUAGUGGUCAGUCCAGG–39 18 bp - - N/D
hE50 AO16PS +92255 9–CUUACAGGCUCCAAUAGUGGUCA–39 23 bp - - N/D
hE50 AO17PS +92210 59–GUAUACUUACAGGCUCCAAUAGUGGUCA–39 28 bp - - N/D
hE50 AO18PS +94214 59–UCCAGUAUACUUACAGGCUCCAAUAGUGGU–39 30 bp - - N/D
hE50 AO19PS +97255 9–CUUACAGGCUCCAAUAGU–39 18 bp 3% - N/D
hE50 AO20PS +97210 59–GUAUACUUACAGGCUCCAAUAGU–39 23 bp - - N/D
hE50 AO21PS +97214 59–UCCAGUAUACUUACAGGCUCCAAUAGU–39 27 bp 1% - N/D
hE50 AO22PS +102214 59–UCCAGUAUACUUACAGGCUCCA–39 22 bp 3% ,1% N/D
hE50 AO23PS +103218 59–GGGAUCCAGUAUACUUACAGGCUCC–39 25 bp 28% 65% N/D
hE50 AO24PS +105214 59–UCCAGUAUACUUACAGGCU–39 19 bp 6% - N/D
hE50 AO25PS +109214 59–UCCAGUAUACUUACA–39 15 bp - - N/D
AON Target PMO AON Sequence L GFP hM DMD
hE50AO5PMO 219+85 9–AACTTCCTCTTTAACAGAAAAGCATAC–39 27 bp 2962%* 2863%* 3463%*
hE50AO12PMO +2+30 59–CCACTCAGAGCTCAGATCTTCTAACTTCC–39 29 bp 966% 4565%* 2564%*
hE50AO14PMO +42+58 59–GCTCTTGAAGTAAACGG–39 17 bp - - -
hE50AO23PMO +103218 59–GGGATCCAGTATACTTACAGGCTCC–39 25 bp 4066%* 8566%* 6265%*
hE50AO26PMO +7+31 59–TCCACTCAGAGCTCAGATCTTCTAA–39 25 bp - - -
hE50AO27PMO +94295 9–TATACTTACAGGCTCCAATAGTGGT–39 25 bp 261% - -
hE50AO28PMO +98216 59–GATCCAGTATACTTACAGGCTCCAATAG–39 28 bp 461% 562% 662%
PS, 2OMePS AO. 2 and + within the Target column indicate the intron and exon sequences respectively; the numbers represent the first and last nucleotides of the
oligonucleotide sequences. Percentage of GFP positive cells with 2OMePS AOs is the average from the flow cytometry analysis. Results from PMO treatment are
presented as mean values 6 SE with statistical analysis (ANOVA) since a completed set of exon skipping efficiency analysis including the in vivo test was conducted with
those PMOs.
*P,0.01 was obtained by comparison of the groups with the hE50AO28PMO groups (n=3). GFP, GFP reporter C2C12hE50 cells; hM, normal human myoblasts. DMD,
DMD patient-derived skin fibroblasts with exon 51 deletion. Scores: -, no positive signal above background is observed for either GFP expression or signals representing
mRNA with exon 50 skipping when compared to the samples of negative controls. Cells were treated with 1 mM AOs. N/D. Muscles of hDMD/mdx mice were treated
with 10 mg Vivi-PMO.
doi:10.1371/journal.pone.0019906.t001
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DMD-patient-derived skin fibroblasts
We next examined the 7 PMO oligomers for hE50 skipping in a
DMD–patient-derived skin fibroblasts (Table 1). The cells
contained the deletion of human dystrophin exon 51 resulting in
a shift in reading frame. Further skipping of the hE50 would
restore the reading frame of the dystrophin mRNA. The
expression of dystrophin mRNA in the fibroblasts was confirmed
by RT-PCR and Nested-PCR. The cells were treated with each
oligomer at the same 1 mM concentration. RT-PCR and Nested-
PCR was used to identify hE50 skipping 3 days after transfection.
Four oligomers demonstrated clearly detectable hE50 skipping
(Table 1). The 3 oligos, hE50AO12PMO, hE50AO5PMO and
hE50AO23PMO produced hE50 skipping with the efficiency up
to 25%, 34% and 62% respectively in repeated experiments
(Figure 2D).
Dose dependent human dystrophin exon 50 skipping
with the hE50AO23PMO
We also further examined the dose response of the
hE50AO23PMO with the highest efficiency as a potential
candidate for further drug development. A dose-dependent
increase in hE50 skipping was observed in all the three cell
culture systems. The efficiency of hE50 skipping was detectable at
50 nM and increased to approximately 70% at 1.6 mM in the
normal human myoblasts (Figure 3A). Skipping efficiency also
reached 64% in the DMD patient derived skin fibroblasts at
0.2 mM concentration. However, skipping efficiency did not
increase significantly further when more than 0.2 mM concentra-
tions were used (Figure 3B). In the C2C12hE50 cells, the
enhanced exon skipping with increasing doses of hE50AO24PMO
exhibited as both increased number of GFP positive cells and the
intensity of the GFP signals within the cells (Figure 3C).
Quantitative flow cytometry analysis further confirmed the dose-
dependent inductions of GFP expression by the hE50AO24PMO,
with up to 54% of the cells expressing GFP at 1.6 mM
concentration (Figure 3D).
Vivo-PMO induced effective dystrophin exon skipping in
muscles of normal C57 mouse
We recently demonstrated that PMOs tagged with arginin-rich
peptide (PPMO) and octa-guanidine (Vivo-PMO) were able to
Figure 1. AOs target human dystrophin exon 50 in C2C12hE50 GFP reporter myoblasts 48 hours after treatment. (A). RT-PCR for the
detection of GFP/hE50 mRNA in the C2C12hE50 cells. Left lane is the 100bp size marker. Con, Control sample without PMO treatment; 12, 5, 23 are
the hE50AOPMOs. The bands marked with +E50 representing normal dystrophin mRNA containing E50; The bands marked with 2E50, representing
dystrophin mRNA with hE50 skipped. The band representing hE50 skipping was most strongly detected in the cells treated with hE50AO23PMO. (B)
and (C) cells treated with the hE50AOPS and hE50AOPMO respectively. (D). FACS analysis for the GFP positive cells treated with the 3 hE50AOPMOs
and the control (without AO treatment).
doi:10.1371/journal.pone.0019906.g001
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[7,8]. We therefore first tested the Vivo-PMOE23 (+07–18) for
targeted skipping of mouse dystrophin exon 23 in the normal C57
mice, so the results can be compared to the exon skipping
efficiency of the same AO in the dystrophic mdx mice [8]. TA
muscles of the C57 mice were injected with 10 mg Vivo-PMOE23
or PMOE23 and examined for the exon23 skipping 2 weeks later.
High levels (approximately 40–70%) of exon 23 skipping were
detected by RT-PCR (without Nested-PCR) in the Vivo-PMOE23
treated muscles whereas skipping was not detectable in the muscles
treated with PMOE23 (Figure 4A). The levels of exon skipping
efficiency were therefore similar to that achieved in the dystrophic
mdx mice [8]. This result confirmed that Vivo-PMO is able to
transfect the normal muscle and induce targeted dystrophin exon
skipping with similar efficiency to that in dystrophic muscles. As
expected, no difference in levels of dystrophin protein was
observed in the muscles between treated and control C57 mice,
due to the fact that the truncated mRNA will be translated into
functional dystrophin protein [4].
Vivo-PMO induced human dystrophin exon 50 skipping
in the hDMD/mdx mice
It is desirable to test the selected AOs targeting human
dystrophin exons in animal models for efficacy as part of AO
drug development. The only available model is the humanized mdx
mouse (hDMD/mdx) [25,31]. To test whether effective skipping
of human dystrophin exon can be achieved in the hDMD/mdx
mice, we first examined 3 most effective PMOs as Vivo-
PMOs, the hE50AO12PMO, Vivo-hE50AO5PMO and Vivo-
hE50AO23PMO for hE50 skipping in comparison with unmod-
ified hE50AO23PMO. Each TA muscle from the mice aged 5–7
weeks received total of 10 mg PMO or Vivo-PMO by intramus-
cular injection and was examined for hE50 skipping by RT-PCR
(without further nested PCR amplification) 5 days later. Human
dystrophin exon 50 skipping was not clearly detected in the
muscles treated with the hE50AO23PMO (Figure 4B). However,
the efficiency of exon skipping reached 2566%, 3464% and
6567% (n=5) with Vivo-hE50AO12PMO, Vivo-hE50AO5PMO
and Vivo-hE50AO23PMO respectively (Figure 4B). Specific
skipping of hE50 was confirmed by subsequent sequencing. No
increases in muscles damage, inflammatory cellular infiltrations, or
necrotic fibers were observed in the muscles treated by any of the
Vivo-PMOs when compared to the PMO (Figure 4C). These
results suggest that Vivo-PMOs can achieve high levels of human
dystrophin exon skipping in the muscle of the hDMD/mdx mice
without notexin pre-treatment which has been required for
inducing human dystrophin exon skipping with untagged PMO
and 2OMePS [26].
Systemic delivery of Vivo-PMOs produced high levels of
human dystrophin exon 50 skipping in both skeletal and
cardiac muscles
We then investigated systemic effects of the two most effective
Vivo-PMOs from the local injection since therapeutic value of
AOs for DMD patients relies on systemic treatment. The Vivo-
hE50AO23PMO and Vivo-hE50AO5PMO at the dose of 15 mg/
kg were injected intravenously into adult (5–7 weeks) hDMD/mdx
mice. Both Vivo-PMOs induced clearly detectable hE50 skipping
by RT-PCR (without Nested-PCR). Vivo-hE50AO23PMO in-
duced more than 70613% skipping efficiency in body-wide
skeletal muscles tested and about 561% in cardiac muscles,
significantly higher than the Vivo-hE50AO5PMO which showed
less than 2065% efficiency in all skeletal muscles, but no
detectable exon skipping in the cardiac muscle (Figure 5A). All
the mice treated with Vivo-PMOs had no weight change when
compared to the controls treated with saline. There was no death
during the treatment period. No clear changes in the levels of
dystrophin expression were detected with immunostaining and
Figure 2. RT-PCR and Nested-PCR for the detection of hE50
skipping in the normal human myoblasts and the DMD-
derived skin fibroblasts. (A). Samples from the normal human
myoblasts cells treated with 2OMePS AOs; (B). Samples from the normal
human myoblasts cells treated with PMOs. +hE50 representing normal
dystrophin mRNA containing hE50; 2hE50, representing dystrophin
mRNA with hE50 skipped. Left lane is the 100 bp size marker; (C). A
sequence showing skipping of the hE50 from the PCR product detected
as –hE50 in the hE50AO24PMO treated normal human myoblasts cells
in (B). (D). The bands marked with +hE50+hE51 representing normal
human dystrophin mRNA (NhM) from normal human myoblasts; the
bands marked with +hE502hE51 representing mRNA from the skin
fibroblasts of a DMD patient with exon 51 deletion; the bands marked
with 2hE50 and –hE51 representing mRNA from the skin fibroblasts
with exon 50 skipped (both exons are absent). Control, without AO
treatment.
doi:10.1371/journal.pone.0019906.g002
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(Figure 5B). However, an increase in serum creatine kinase level
was observed in the mice treated with the Vivo-PMOs (Figure 5C),
suggesting a low level disturbance in membrane integrity possibly
due to the slight reduction in dystrophin protein in some muscles
as the mouse expresses the dystrophin only from the human
dystrophin gene. The levels of other serum enzymes including
ALT in the Vivo-PMOs-treated mice remained similar to those in
the control mice (Figure 5C). Consistently no changes were
observed in the muscles, liver and kidney by histology.
Discussion
More than 1 and half decades ago, Kole and his colleagues first
introduced AOs as splicing regulators for correcting inherited
genetic disorder, Thalassemia. By blocking the aberrant splice sites
sterically in the mutated b-globin gene, specific AO was able to
restore the normal splicing pattern of the gene [28]. Since then,
the same principle has been developed into a highly promising
experimental therapy for the DMD. For this application, AOs are
used as the drugs for skipping targeted dystrophin exons to restore
Figure 3. Dose dependent human dystrophin exon 50 skipping with the hE50AO23PMO in normal human myoblast and skin
fibroblasts of a DMD patient with exon 51 deletion. The signal intensity of the strongest bands representing exon 50 skipping was 71% and
65% in the normal human myoblas (A) and skin fibroblasts (B) respectively (measured with NIH ImagJ). (C). C2C12hE50 reporter myoblasts. (D). FACS
analysis of the C2C12hE50 reporter cells treated with the hE50AO23PMO with the concentrations specified.
doi:10.1371/journal.pone.0019906.g003
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Given that AO-mediated exon skipping is principally a drug
therapy, one of the most critical factors for high efficacy of the
remedy is the identification of effective AOs. Ideally, AO drugs
targeting specific human dystrophin exon should be selected first
in cell culture systems representing the targeted cells in human and
the efficacy of the selected AOs will then be validated in vivo in
animal models before the selected AOs are considered for further
drug development including expensive toxicology and pharma-
cology tests. These requirements however have been difficult to
meet as human muscle fibers can not be maintained in culture
long enough for AO tests and no dystrophic animal models
containing human dystrophin gene with specific DMD mutations
exist. Currently the most widely used model for AO selection have
been the human myoblast culture system. The relevance of AOs
selected through the cultures to the efficiency in vivo has been to a
certain extent supported with the AOs targeting mouse dystrophin
exon 23 and human dystrophin exon 51 in the mdx mice and in the
afore mentioned clinic trials [16]. These results suggest that the
majority of AOs selected in the myoblast culture is likely to have
the potential to skip the targeted exon in vivo. However,
discrepancy in skipping efficiency between in cell culture and in
vivo in animal models with same AO has been reported. In the
dystrophic dog model, one highly effective AO selected in culture
of the dog’s myoblasts was later found to be of limited exon
skipping efficacy in vivo [10]. This raises the concern that selected
AO through myoblast cultures alone may fail to achieve expected
efficiency in muscle fibers in vivo for targeted exons, a risk too
costly to be ignored. In this study, we also observed discrepancy in
efficiency of exon skipping between cell cultures and the hDMD/
mdx mice in vivo with some AOs. While the hE50AO23PMO
consistently induced highest hE50 skipping in all cell culture
systems and in the hDMD/mdx mice in vivo, the relative efficiency
of hE50 skipping with hE50AO12PMO and hE50AO5PMO
varies in different systems. The hE50AO12PMO induced clearly
higher efficiency in the human myoblasts than hE50AO5PMO,
whereas the hE50AO5PMO induced higher skipping efficiency in
the reporter cells, DMD-derived fibroblasts and in the muscles of
hDMD/mdx mice. Although discrepancy in exon skipping
efficiency in different testing systems is not a common feature
for most AOs tested in this study, our finding further suggest that
caution needs to be excised to minimize the risk of selecting AO
with lower efficiency in vivo for antisense drug development.
One limitation for using myoblast culture to select AO is the
relative low sensitivity of the system to distinguish AOs with similar
exon skipping efficiency, but the difference between such AOs
could be significant when applied to the patients in clinics. This is
because evaluation of targeted exon skipping efficiency in human
Figure 4. Effect of Vivo-PMO for dystrophin exon skipping in tibialis anterior (TA) muscles of normal C57 mice and in the hDMD/
mdx mice. (A). The signal intensity of the bands representing mouse dystrophin exon 23 skipping with Vivo-PMOE23 from normal C57 mice was
7067%. (B). Signal intensity of the bands representing human dystrophin exon 50 skipping after Vivo-hE50AO23PMO treatment from the hDMD/mdx
mice was 6567%, significantly higher when compared with 2566%, 3464% detected after Vivo-hE50AO12PMO and Vivo-hE50AO5PMO treatment.
Results from 2 TA muscles for each Vivo-PMO are presented. Signal intensity was measured with NIH Image J. Results are presented as mean values 6
SE with statistical analysis (t-test). *P,0.01 was obtained by comparison of the group(s) with PMOE23 and hE50AO12PMO group in (A) and (B)
respectively (n=5). (C). H&E staining of the TA muscles treated with Vivo-PMOs. No change in muscle histology was detected. Control, saline injected
TA muscle.
doi:10.1371/journal.pone.0019906.g004
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PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e19906Figure 5. Effect of Vivo-PMO for human dystrophin exon 50 skipping systemically in the hDMD/mdx mice. TA, tibialis anterior; Quad,
quadriceps; Gastro, gastronemium; Abdom, abdominal; Diaph, diaphragm. The signal intensity of the bands representing human dystrophin exon 50
skipping was 70613% and 561%, 2065% and 0% in body-wide skeletal muscles and cardiac muscles treated with Vivo-hE50AO23PMO and Vivo-
hE50AO5PMO respectively (measured with NIH ImagJ) (A). Results are presented as mean values 6 SE with statistical analysis (t-test). *P,0.01 was
obtained by comparison of the Vivo-hE50AO23PMO group with the hE50AO5PMO group. (n=5) (B). Immunohistochemical staining shows similar
intensity for dystrophin after the Vivo-PMO treatments in all muscles tested. (C). Serum enzyme tests show a slight increase in the levels of creatine
kinase in the mice treated with Vivo-PMOs.
doi:10.1371/journal.pone.0019906.g005
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second round Nested-PCR, which together with the initial RT-
PCR procedure, has a degree of variation to determine the relative
amount of transcripts from different samples. It is therefore
apparently insufficient to select AO for further drug development
based on Nested-PCR alone in myoblast culture and desirable to
search for culture systems with higher sensitivity and better
quantification to evaluate exon skipping efficiency [32]. Confir-
mation of AO with high efficiency for specific exon skipping in
additional screening system would also suggest a higher probability
for the selected AO to be effective in wider cellular environments,
thus in human muscles of different DMD patients in vivo. Here we
explored the use of a GFP reporter myoblast culture system for
screening AOs targeting human dystrophin exon. The system was
originally established by Kole and his colleagues to identify AO
sequences for effective blocking of the aberrant splicing site in the
mutated b-globin gene [28]. We found that the reporter system is
more sensitive for identifying AOs capable of skipping human
dystrophin exon 50 than the human myoblast culture. The exon
skipping efficiency of individual AO demonstrated in the reporter
cells is in general consistent to that observed in the human
myoblasts. More importantly, the GFP reporter system provides
direct visual presentation under microscope for the targeted exon
skipping and quantitative measurement of the skipping efficiency.
These together with the fact that chimeric GFP/hE50 RNA can
be stably expressed at high levels provide greater capability to
distinguish the differential antisense effect with individual AOs.
Thus, although the reporter system cannot replace the myoblast
cultures for AO screening, the advantages make it a valuable
additional screening system. A combined use of the GFP-based
reporter with human myoblast cultures and cells from applicable
DMD patients would be better suited for selection of AOs
targeting human dystrophin exon in vitro.
Traditional drug development requires validation of the efficacy
in animal models of same disease entity. Antisense therapy for
DMD uses AOs complementary to human dystrophin RNA.
Therefore, animal models in general are not useful for efficacy
validation due to species specificity of gene sequence. This poses a
significant hurdle for AO drug development as drug developers
will be unable to validate the efficacy of AO targeting human
dystrophin exon in animal models, which is generally considered
to be essential for regulatory approval of clinic trials. To mitigate
the problem, van Deutekom’s group in Netherlands created a
transgenic mouse containing the entire human dystrophin gene
[25]. A human dystrophin gene transgenic mdx mouse was also
produced by crossbreeding with the mdx mouse (hDMD/mdx).
However, expression of the normal human dystrophin compen-
sates for the deficiency in mouse dystrophin protein. The hDMD/
mdx mouse therefore is phenotypically normal, which severely
limits the delivery efficiency of AOs of both chemistries, 2OMePS
and PMO [26,29]. Limited skipping of human dystrophin exon in
the mouse had so far been achieved in local muscles only after
notexin pretreatment [26]. However, we and others recently
reported that the PPMO and Vivo-PMO were able to deliver the
PMO oligomers effectively into near 100% of skeletal and cardiac
muscles of the mdx mice without notexin pretreatment [7,8]. Since
the cardiac muscle and a proportion of skeletal muscle fibers in the
mouse are of limited pathology, the results suggest that the tagged
PMOs could be used to target apparently normal muscles for exon
skipping systemically. This notion was first proved in the C57
normal mice with the Vivo-PMOE23 targeting mouse exon 23.
Up to 70% efficiency in exon 23 skipping was achieved in the TA
muscles when examined by RT-PCR. This efficiency at the
mRNA level is similar to that observed in the dystrophic mdx mice
with the same Vivo-PMO. This result together with the
demonstration that similar efficiency can also be achieved for
skipping human dystrophin exon 50 in the hDMD/mdx mouse
clearly indicate that the hDMD/mdx mouse becomes a valuable
model for testing AOs targeting human dystrophin when Vivo-
PMO is used. Furthermore, systemic efficiency established with
the known AOs in vivo, such as that with PMOE23 targeting
mouse exon 23 could be used as a reference to assess the potential
efficacy of AO targeting human dystrophin exon in vivo. With the
efficacy of AOs targeting human dystrophin exon 51 may soon
become available, systemic efficiency of any newly selected AOs
can then be compared directly to that of the AO targeting exon 51
in the hDMD/mdx mice. Different dose regimens may also be
formulated to assess desirable therapeutic effect systemically. This
is especially useful for antisense therapy to DMD as many AO
drugs are required for the treatment of majority of DMD boys.
In summary, our results demonstrate that a GFP-based reporter
myoblast culture is a sensitive screening system for selection of
AOs targeting human dystrophin exons. The use of Vivo-PMO
enables AOs targeting human dystrophin exons to be examined in
the hDMD/mdx mouse in vivo systemically, which is essential for
drug development and regulatory approval. The effective
hE50AO23 sequence identified in this study has now been further
validated and selected by AVI Biopharma for further drug
development targeting hE50. AOs selected by a combination of in
vitro and in vivo tests are likely more robust to provide a high
efficacy in patients.
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